BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11. [PMID: 27080498 DOI: 10.1016/S0140-6736(15)01317-3] [Cited by in Crossref: 106] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
Number Citing Articles
1 Kwon YS, Munshi F, Patel NR, Serei V, Patel N, Drachtman RA, Barone JG. An Isolated Testicular Relapse of Burkitt's Lymphoma. Glob Pediatr Health 2019;6:2333794X19872427. [PMID: 31516915 DOI: 10.1177/2333794X19872427] [Reference Citation Analysis]
2 Richard-Carpentier G, Kantarjian H, Jabbour E. Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 2019;14:106-18. [PMID: 30879177 DOI: 10.1007/s11899-019-00503-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zhao J, Song Y, Liu D. Recent advances on blinatumomab for acute lymphoblastic leukemia. Exp Hematol Oncol 2019;8:28. [PMID: 31709129 DOI: 10.1186/s40164-019-0152-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
4 Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017;376:836-47. [PMID: 28249141 DOI: 10.1056/NEJMoa1609783] [Cited by in Crossref: 772] [Cited by in F6Publishing: 342] [Article Influence: 154.4] [Reference Citation Analysis]
5 Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother 2018;14:2820-41. [PMID: 30096012 DOI: 10.1080/21645515.2018.1508624] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
6 Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C. Molecular Update and Evolving Classification of Large B-Cell Lymphoma. Cancers (Basel) 2021;13:3352. [PMID: 34283060 DOI: 10.3390/cancers13133352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 2017;92:E114-7. [PMID: 28295472 DOI: 10.1002/ajh.24720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
8 Ribera JM, Genescà E, Ribera J. Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. Ther Adv Hematol 2020;11:2040620720919632. [PMID: 32523659 DOI: 10.1177/2040620720919632] [Reference Citation Analysis]
9 Patekar M, Gogia A, Tiwari A, Kumar L, Sharma A, Mallick SR, Sharma MC, Thulkar S, Gupta R. Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol. South Asian J Cancer 2018;7:195-9. [PMID: 30112340 DOI: 10.4103/sajc.sajc_230_17] [Reference Citation Analysis]
10 Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, Zoufaly A, Wasmuth JC, Bogner JR, Müller M, Esser S, Schleicher A, Jensen B, Stoehr A, Behrens G, Schultze A, Siehl J, Thoden J, Taylor N, Hoffmann C. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica 2018;103:857-64. [PMID: 29439188 DOI: 10.3324/haematol.2017.180893] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
11 Greenbaum U, Mahadeo KM, Kebriaei P, Shpall EJ, Saini NY. Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Front Oncol 2020;10:1594. [PMID: 32984022 DOI: 10.3389/fonc.2020.01594] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma., Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 2020;382:2207-19. [PMID: 32492302 DOI: 10.1056/NEJMoa1915315] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 14.5] [Reference Citation Analysis]
13 Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol 2019;12:15. [PMID: 30736842 DOI: 10.1186/s13045-019-0703-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
14 Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging 2019;10:56. [PMID: 31115699 DOI: 10.1186/s13244-019-0733-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
15 Liu ZL, Liu PP, Bi XW, Lei DX, Wang Y, Li ZM, Jiang WQ, Xia Y. Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis. Cancer Med 2019;8:874-81. [PMID: 30706675 DOI: 10.1002/cam4.1870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 2017;8:11-29. [PMID: 28096698 DOI: 10.2147/AHMT.S94170] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
17 Wang Z, Chen M, Fang X, Hong H, Yao Y, Huang H. KIF15 is involved in development and progression of Burkitt lymphoma. Cancer Cell Int 2021;21:261. [PMID: 33985517 DOI: 10.1186/s12935-021-01967-z] [Reference Citation Analysis]
18 Stepanov AV, Markov OV, Chernikov IV, Gladkikh DV, Zhang H, Jones T, Sen'kova AV, Chernolovskaya EL, Zenkova MA, Kalinin RS, Rubtsova MP, Meleshko AN, Genkin DD, Belogurov AA Jr, Xie J, Gabibov AG, Lerner RA. Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv 2018;4:eaau4580. [PMID: 30443597 DOI: 10.1126/sciadv.aau4580] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ge X, Chen J, Li L, Ding P, Wang Q, Zhang W, Li L, Lv X, Zhou D, Jiang Z, Zeng H, Xu Y, Hou Y, Hu W. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. Cell Death Dis 2018;10:8. [PMID: 30584254 DOI: 10.1038/s41419-018-1259-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Zayac AS, Olszewski AJ. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma 2020;61:1784-96. [PMID: 32255708 DOI: 10.1080/10428194.2020.1747068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. Int J Mol Sci 2021;22:2150. [PMID: 33670075 DOI: 10.3390/ijms22042150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
23 Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol 2019;12:17. [PMID: 30764841 DOI: 10.1186/s13045-019-0705-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
24 Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer 2021. [PMID: 34614211 DOI: 10.1002/cncr.33933] [Reference Citation Analysis]
25 Aujla A, Aujla R, Liu D. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res 2019;7:9. [PMID: 31011424 DOI: 10.1186/s40364-019-0160-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
26 Zhao Q, Li J, Wu B, Shang Y, Huang X, Dong H, Liu H, Gui R, Nie X. A Nano-Traditional Chinese Medicine Against Lymphoma That Regulates the Level of Reactive Oxygen Species. Front Chem 2020;8:565. [PMID: 32766207 DOI: 10.3389/fchem.2020.00565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood 2018;132:369-75. [PMID: 29895666 DOI: 10.1182/blood-2018-02-778480] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
28 Chen J, Kendrick S, Qin Z. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses 2019;11:E1161. [PMID: 31888174 DOI: 10.3390/v11121161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Robert A, Pujals A, Favre L, Debernardi J, Wiels J. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders. Mol Oncol 2020;14:2520-32. [PMID: 32623836 DOI: 10.1002/1878-0261.12759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Granai M, Mundo L, Akarca AU, Siciliano MC, Rizvi H, Mancini V, Onyango N, Nyagol J, Abinya NO, Maha I, Margielewska S, Wi W, Bibas M, Piccaluga PP, Quintanilla-Martinez L, Fend F, Lazzi S, Leoncini L, Marafioti T. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infect Agent Cancer 2020;15:28. [PMID: 32391073 DOI: 10.1186/s13027-020-00292-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol 2018;8:163. [PMID: 29915719 DOI: 10.3389/fonc.2018.00163] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 21.5] [Reference Citation Analysis]
32 Li L, Wang Y. Recent updates for antibody therapy for acute lymphoblastic leukemia. Exp Hematol Oncol 2020;9:33. [PMID: 33292550 DOI: 10.1186/s40164-020-00189-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Liu D. Cancer biomarkers for targeted therapy. Biomark Res 2019;7:25. [PMID: 31807308 DOI: 10.1186/s40364-019-0178-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
34 Penther D, Viailly PJ, Latour S, Etancelin P, Bohers E, Vellemans H, Camus V, Menard AL, Coutant S, Lanic H, Lemasle E, Drieux F, Veresezan L, Ruminy P, Raimbault A, Soulier J, Frebourg T, Tilly H, Jardin F. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. Genes Chromosomes Cancer 2019;58:595-601. [PMID: 30779244 DOI: 10.1002/gcc.22743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Pereira RF, Mauro GP, Medici CTM, Casimiro LC, Weltman E. Radiotherapy in Adult Burkitt Lymphoma: A Retrospective Analysis in a Large University Center. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01495-w] [Reference Citation Analysis]
36 Raatz M, Shah S, Chitadze G, Brüggemann M, Traulsen A. The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics. PLoS Comput Biol 2021;17:e1008702. [PMID: 33577569 DOI: 10.1371/journal.pcbi.1008702] [Reference Citation Analysis]
37 Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 2019;125:2579-86. [PMID: 30985931 DOI: 10.1002/cncr.32139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
38 Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open 2019;9:e024537. [PMID: 30826796 DOI: 10.1136/bmjopen-2018-024537] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
39 Yang D, Wang P, Chen J, Li CX, Zhang Y, Chen XC, Wu DP. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2018;39:645-9. [PMID: 30180465 DOI: 10.3760/cma.j.issn.0253-2727.2018.08.007] [Reference Citation Analysis]
40 Habbous S, Guo H, Beca J, Dai WF, Isaranuwatchai W, Cheung M, Chan KKW. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. Cancer Med 2020;9:7072-82. [PMID: 32794362 DOI: 10.1002/cam4.3362] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv 2016;1:260-4. [PMID: 29296940 DOI: 10.1182/bloodadvances.2016000042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica 2021;106:1932-42. [PMID: 33538152 DOI: 10.3324/haematol.2020.270876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Tabata M, Tsubaki M, Takeda T, Tateishi K, Tsurushima K, Imano M, Satou T, Ishizaka T, Nishida S. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells. BMC Complement Med Ther 2020;20:84. [PMID: 32171300 DOI: 10.1186/s12906-020-2879-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Boissel N, Rabian F. Immunotherapies in acute leukemia. Therapie 2021:S0040-5957(21)00252-3. [PMID: 34924207 DOI: 10.1016/j.therap.2021.12.003] [Reference Citation Analysis]
45 Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol 2019;10:2040620719849496. [PMID: 31205644 DOI: 10.1177/2040620719849496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
46 Painschab MS, Westmoreland KD, Kasonkanji E, Zuze T, Kaimila B, Waswa P, El-Mallawany NK, Tomoka T, Mulenga M, Montgomery ND, Fedoriw Y, Gopal S. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv 2019;3:612-20. [PMID: 30796065 DOI: 10.1182/bloodadvances.2018029199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
47 Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol 2020;38:2519-29. [PMID: 32453640 DOI: 10.1200/JCO.20.00303] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
48 Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther 2017;34:2232-73. [PMID: 28983798 DOI: 10.1007/s12325-017-0612-x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 169] [Article Influence: 32.0] [Reference Citation Analysis]
49 Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, Ribrag V. Burkitt and Burkitt-Like Lymphomas: a Systematic Review. Curr Oncol Rep 2020;22:33. [PMID: 32144513 DOI: 10.1007/s11912-020-0898-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
50 Leonard J, Stock W. Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program 2017;2017:28-36. [PMID: 29222234 DOI: 10.1182/asheducation-2017.1.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Li H, Chi X, Li R, Ouyang J, Chen Y. HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. Int J Biol Sci 2019;15:2438-47. [PMID: 31595161 DOI: 10.7150/ijbs.38146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
52 Tan JY, Qiu TY, Chiang J, Tan YH, Yang VS, Chang EWY, Poon E, Somasundaram N, Farid M, Tao M, Lim ST, Chan JY. Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leukemia & Lymphoma. [DOI: 10.1080/10428194.2022.2027402] [Reference Citation Analysis]